New Treatment for Cutaneous T-Cell Lymphoma Fast-Tracked

soligenix.jpg

According to biopharmaceutical company Soligenix, the US Food and Drug Administration has fast-tracked the company's experimental treatment SGX301 for the front-line treatment of patients with cutaneous t-cell lymphoma (CTCL).

SGX301, synthetic hypericin, is listed as a first-in-class photodynamic therapy. It uses safe visible light for activation. Synthetic hypericin is a photosensitizer applied topically to skin lesions and then activated by using fluorescent light. Pre-clinical and clinical studies have shown that hypericin combined with photoactivation can have significant antiproliferative effects on activated normal lymphoid cells and can contribute to inhibiting the growth of malignant T-cells in patients diagnosed with CTCL.

A phase II study of SGX301 in CTCL patients showed a statistically significant improvement in patients using the topical SGX301 (58.3 percent) compared to patients given a placebo (8.3 percent).

Read more about SGX301 at Soligenix.com.

Adapted from press release.

LymphomaInfo Social